{
    "clinical_study": {
        "@rank": "119527", 
        "arm_group": {
            "arm_group_label": "Cohort"
        }, 
        "brief_summary": {
            "textblock": "This observational study will collect data about safety in female patients with advanced\n      ovarian epithelial cancer with measurable residual disease after surger y. The treating\n      physician has decided to treat the patients with Avastin (bevaci zumab) in combination with\n      chemotherapy followed by Avastin monotherapy accordin g to the local label. Data will be\n      collected for 72 weeks."
        }, 
        "brief_title": "An Observational Study of Avastin (Bevacizumab) in Patients With Ovarian Cancer", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "condition": "Ovarian Cancer", 
        "condition_browse": {
            "mesh_term": "Ovarian Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Female patients over 18 years of age\n\n          -  Histologically confirmed Advanced Epithelial Ovarian Cancer\n\n          -  Confirmed ascites prior to surgery\n\n          -  Residual disease after surgery\n\n          -  Patients are chemotherapy na\u00efve or have received only one prior line of treatment for\n             their disease\n\n          -  International Federation of Gynecology and Obstetrics (FIGO) stage IIIb or IV disease\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status <=2\n\n          -  Patients must meet treatment eligibility requirements according to treating physician\n             and Summary of Product Characteristics (SmPC) criteria for Avastin plus chemotherapy.\n\n        Exclusion Criteria:\n\n          -  Pregnancy or lactation\n\n          -  Low grade tumors, since this does not necessarily requires systemic treatment.\n             Complete surgical resection\n\n          -  Uncontrollable hypertension\n\n          -  Unexplained bleeding\n\n          -  Known hypersensitivity to any components of bevacizumab\n\n          -  All contraindications specified in the respective Summary of Product Characteristics\n             (SmPC) and/or local labelling of Avastin and the corresponding chemotherapy must be\n             adhered to by the physician."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Female patients with Advanced FIGO Stage (IIIb to IV) Ovarian Epithelial Cancer with\n        measurable residual disease after surgery"
            }
        }, 
        "enrollment": {
            "#text": "3", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02151370", 
            "org_study_id": "ML28428"
        }, 
        "intervention_browse": {
            "mesh_term": "Bevacizumab"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 28, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Salvador", 
                    "country": "El Salvador", 
                    "zip": "01101"
                }
            }
        }, 
        "location_countries": {
            "country": "El Salvador"
        }, 
        "number_of_groups": "1", 
        "official_title": "Ascites Control Treating Ovarian Cancer With Bevacizumab: \"ACT-OB\"", 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "El Salvador: Ministry of Health"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "The proportion of patients who require paracenthesis during treatment with Avastin", 
                "safety_issue": "No", 
                "time_frame": "72 weeks"
            }, 
            {
                "measure": "The amount of ascitic fluid extracted during treatment with Avastin", 
                "safety_issue": "No", 
                "time_frame": "72 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02151370"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Safety: Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "72 weeks"
            }, 
            {
                "measure": "To evaluate Eastern Cooperative Oncology Group (ECOG) performance status before and after start of therapy", 
                "safety_issue": "No", 
                "time_frame": "72 weeks"
            }, 
            {
                "measure": "To determine regional epidemiologic data for the studied population", 
                "safety_issue": "No", 
                "time_frame": "72 weeks"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}